- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome treated with LIVMARLI
- Data are the first to demonstrate a six-year transplant-free.
Mirum Pharmaceuticals, Inc. today announced that Hepatology published an analysis demonstrating a statistically significant improvement in six-year event-free and transplant-free survival in patients with Alagille syndrome (ALGS) treated with.
FY2026 EPS Estimates for Mirum Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:MIRM) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $54.13 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.